Review Finds Personalized Neoantigen Vaccines Can Improve Early Disease Outcomes - Bioengineer.org
A review by Adrien P. Mouren and Patrick A. Ott in Nature Reviews Clinical Oncology concludes that personalized neoantigen vaccines can improve clinical outcomes, particularly when deployed in earlier disease settings and integrated with broader immunotherapeutic strategies. The authors contrast this with early-generation vaccines targeting shared self-antigens, which were limited by central immunological tolerance and suboptimal T cell priming despite inducing measurable immune responses. The core challenge remains converting reliable tumor-specific immunogenicity into durable tumor control. The review credits advances in neoantigen identification, vaccine technologies, immune profiling, and computational biology for renewing the field — a reminder that prediction and biomarker tooling, not just antigens, are the differentiators.